Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
Iterum Therapeutics plc - Ordinary Share (ITRM)
Last iterum therapeutics plc - ordinary share earnings: 11/12 04:30 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 2 clinical trial in complicated urinary tract infections (cUTI). “The completion of enrollment in our cUTI trial marks the achievement of another critical milestone in our development program,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “Completing enrollment in this phase 3 trial brings us another step closer to providing physicians and patients with the first and only oral and intravenous (IV) penem antibiotic, if approved. We look forward to sharing topline results from the SURE 2 trial in early 2020.” This multi-center, double-blind clinical t
Show less
Read more
Impact Snapshot
Event Time:
ITRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITRM alerts
High impacting Iterum Therapeutics plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
ITRM
News
- Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024GlobeNewswire
- Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat [Yahoo! Finance]Yahoo! Finance
ITRM
Earnings
- 3/28/24 - Beat
ITRM
Sec Filings
- 4/5/24 - Form 8-K
- 3/29/24 - Form 8-K
- 3/28/24 - Form 10-K
- ITRM's page on the SEC website